GSK Submits TYVERB(R)/TYKERB(R) (lapatinib) For First-Line Treatment Of Metastatic Breast Cancer In Europe, US

News — By on April 2, 2009 at 4:00 am

GlaxoSmithKline (NYSE: GSK) announced the submission of two simultaneous regulatory applications to expand the use of TYVERB(R)/TYKERB(R) (lapatinib). If approved, TYVERB(R)/TYKERB(R) could be used as a first-line therapy regimen combined with anti-hormonal therapy for patients with hormone-sensitive, metastatic (or advanced) breast cancer in Europe and the United States.

Please read the complete article and let us know what you think below.

Leave a Reply

Trackbacks

Leave a Trackback